234 related articles for article (PubMed ID: 30055340)
1. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
[TBL] [Abstract][Full Text] [Related]
2. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
[TBL] [Abstract][Full Text] [Related]
3. Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD).
Crabtree NJ; Roper H; Shaw NJ
Bone; 2022 Jan; 154():116248. PubMed ID: 34718220
[TBL] [Abstract][Full Text] [Related]
4. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
[TBL] [Abstract][Full Text] [Related]
5. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
[TBL] [Abstract][Full Text] [Related]
6. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
Mayo AL; Craven BC; McAdam LC; Biggar WD
Neuromuscul Disord; 2012 Dec; 22(12):1040-5. PubMed ID: 22824639
[TBL] [Abstract][Full Text] [Related]
7. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
[TBL] [Abstract][Full Text] [Related]
8. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
[TBL] [Abstract][Full Text] [Related]
9. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
[TBL] [Abstract][Full Text] [Related]
11. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
[TBL] [Abstract][Full Text] [Related]
12. Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy.
Lee SL; Lim A; Munns C; Simm PJ; Zacharin M
Horm Res Paediatr; 2020; 93(2):108-118. PubMed ID: 32610327
[TBL] [Abstract][Full Text] [Related]
13. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
Kao KT; Joseph S; Capaldi N; Brown S; Di Marco M; Dunne J; Horrocks I; Shepherd S; Ahmed SF; Wong SC
Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
[TBL] [Abstract][Full Text] [Related]
14. Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment.
Tung JY; Lam TP; Chan SH
J Bone Miner Metab; 2021 Jul; 39(4):606-611. PubMed ID: 33400004
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Wilson N; Walker S; Hartigan C; Khan N; Page M; Robinson ME; Saleh DS; Smit K; Rauch F; Siminoski K; Ward LM
J Clin Endocrinol Metab; 2024 Jan; 109(2):536-548. PubMed ID: 37610420
[TBL] [Abstract][Full Text] [Related]
16. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.
Hawker GA; Ridout R; Harris VA; Chase CC; Fielding LJ; Biggar WD
Arch Phys Med Rehabil; 2005 Feb; 86(2):284-8. PubMed ID: 15706555
[TBL] [Abstract][Full Text] [Related]
17. Fractures and bone health monitoring in boys with Duchenne muscular dystrophy managed within the Scottish Muscle Network.
Joseph S; Wang C; Di Marco M; Horrocks I; Abu-Arafeh I; Baxter A; Cordeiro N; McLellan L; McWilliam K; Naismith K; Stephen E; Ahmed SF; Wong SC
Neuromuscul Disord; 2019 Jan; 29(1):59-66. PubMed ID: 30473133
[TBL] [Abstract][Full Text] [Related]
18. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
Singh A; Schaeffer EK; Reilly CW
J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
[TBL] [Abstract][Full Text] [Related]
19. Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.
Catalano A; Vita GL; Bellone F; Sframeli M; Distefano MG; La Rosa M; Gaudio A; Vita G; Morabito N; Messina S
J Endocrinol Invest; 2022 Mar; 45(3):517-525. PubMed ID: 34524678
[TBL] [Abstract][Full Text] [Related]
20. Growth pattern trajectories in boys with Duchenne muscular dystrophy.
Stimpson G; Raquq S; Chesshyre M; Fewtrell M; Ridout D; Sarkozy A; Manzur A; Ayyar Gupta V; De Amicis R; Muntoni F; Baranello G;
Orphanet J Rare Dis; 2022 Jan; 17(1):20. PubMed ID: 35073949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
